Optimized Therapy of Infectious Diseases and Cancer Using Carrier Nanopeptide

Therapeutic protocols used to treat infectious diseases (mainly leishmaniasis) and cancer are performed with obsolete drugs, which present failures, relapses and side effects, such as cardio and nephrotoxicity, mainly.

In addition, drug production costs are high, as it is necessary to use high concentrations of active principle in formulations.

Thus, the cost of treatment for the patient will be higher, not only due to the price of the drug, but also due to the extension of the therapeutic scheme.

Optimization of the current therapy, through additive or synergistic pharmacological effect, using antiparasitic and antitumor drugs associated with a carrier nanopeptide (Crotamine toxin).
The use of the carrier will increase the intracellular effect (pharmacological efficiency), from lower concentrations of the drugs used in the therapy.
With less circulating drug, users will have optimized therapy on target and experience fewer adverse side effects. In addition, by reducing the need to use high doses in the treatment, it is possible to reduce the costs of production and the final treatment for the patient.

Partnership with national and international pharmaceutical and/or biotechnology-based companies with IDP capacity to validate or increase the technology in their drug portfolio, as well as those interested in the possible transfer of technology for the future commercialization of “optimized drugs” for the treatment of target-diseases.